Cocrystal Pharma (COCP)
(Delayed Data from NSDQ)
$2.35 USD
0.00 (0.00%)
Updated Jul 19, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
COCP 2.35 0.00(0.00%)
Will COCP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for COCP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for COCP
Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?
COCP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for COCP
Cocrystal Pharma (COCP) Receives a Buy from Noble Financial
Cocrystal Pharma reports results from SAD cohorts of Phase 1 study with CDI-988
Noble Financial Sticks to Its Buy Rating for Cocrystal Pharma (COCP)
Cocrystal Pharma’s Promising Antiviral Candidate for Influenza A
New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows